{"id":7862,"date":"2024-12-02T20:58:50","date_gmt":"2024-12-02T12:58:50","guid":{"rendered":"https:\/\/regask.com\/?p=7862"},"modified":"2024-12-02T20:58:50","modified_gmt":"2024-12-02T12:58:50","slug":"zulassung-von-arzneimitteln-durch-die-nmpa-in-china","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/china-nmpa-drug-review-approval\/","title":{"rendered":"NMPA genehmigt ersten Antrag auf klinische Studie im Rahmen von Pi\u2026"},"content":{"rendered":"<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"2451705a-75cb-46e1-baee-db0ea4fb0cfa\" data-message-model-slug=\"gpt-4o\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>On November 15, 2024, China\u2019s National Medical Products Administration (NMPA) announced a milestone in its pilot program designed to optimize the review and approval processes for innovative drugs. This initiative aims to streamline clinical trial applications, improving both efficiency and quality.<\/p>\n<h4>Key Highlights<\/h4>\n<ul>\n<li><strong>First Approval:<\/strong><br \/>\nThe first clinical trial application approved under the pilot program is for an injectable drug for advanced solid tumors. The trial will be conducted by <strong>Peking University Cancer Hospital<\/strong>.<\/li>\n<li><strong>Faster Review Process:<\/strong><br \/>\nThe review was completed in just <strong>21 days<\/strong>, showcasing a significant improvement in processing times compared to traditional procedures.<\/li>\n<li><strong>Scope of the Pilot Program:<\/strong>\n<ul>\n<li>A total of <strong>nine clinical trials<\/strong> have been included in the pilot work plan.<\/li>\n<li>Five of these trials have submitted Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE), all of which have been accepted for review.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Enhanced Collaboration:<\/strong><br \/>\nThe program prioritizes closer communication and collaboration among evaluation agencies, local regulatory authorities, applicants, and medical institutions. This approach aims to maintain high-quality standards while expediting the application process.<\/li>\n<\/ul>\n<h4>Implications<\/h4>\n<p>The successful approval under this pilot program marks a promising step in <a href=\"https:\/\/regask.com\/china-cosmetics-monitoring-focus\/\">China\u2019s efforts<\/a> to encourage innovation in drug development. By significantly reducing review timelines and fostering collaboration, the initiative supports the rapid advancement of treatments for critical conditions like advanced tumors.<\/p>\n<h4>Next Steps<\/h4>\n<p>Stakeholders should monitor the progress of the pilot program and its impact on clinical trial efficiency. Companies planning to develop innovative drugs in China may find this program beneficial and should explore opportunities to participate in similar initiatives.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\">\n<div class=\"flex items-center\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Am 15. November 2024 gab die chinesische Arzneimittelbeh\u00f6rde (NMPA) einen Meilenstein in ihrem Pilotprogramm zur Optimierung der Pr\u00fcf- und Zulassungsverfahren f\u00fcr innovative Arzneimittel bekannt. Ziel dieser Initiative ist die Straffung der Antr\u00e4ge f\u00fcr klinische Studien, um Effizienz und Qualit\u00e4t zu verbessern. Wichtigste Ergebnisse: Erste Zulassung: Der erste Antrag f\u00fcr eine klinische Studie wurde im Rahmen des Pilotprogramms zugelassen\u2026<\/p>","protected":false},"author":43,"featured_media":7872,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[497,498,591],"class_list":["post-7862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-oncology","tag-drug-development-regs","tag-clinical-trial-regulations"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China NMPA&#039;s New Drug Review &amp; Approval Process | RegASK<\/title>\n<meta name=\"description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/zulassung-von-arzneimitteln-durch-die-nmpa-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs\" \/>\n<meta property=\"og:description\" content=\"China&#039;s NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/zulassung-von-arzneimitteln-durch-die-nmpa-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T12:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"NMPA Approves First Clinical Trial Application Under Pi&hellip;\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"keywords\":[\"Oncology\",\"Drug Development Regs\",\"Clinical Trial Regulations\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\",\"name\":\"China NMPA's New Drug Review & Approval Process | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"datePublished\":\"2024-12-02T12:58:50+00:00\",\"description\":\"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/china-nmpa-drug-review-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png\",\"width\":800,\"height\":600,\"caption\":\"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u00dcberpr\u00fcfungs- und Zulassungsverfahren f\u00fcr neue Arzneimittel der chinesischen NMPA | RegASK","description":"Die chinesische NMPA f\u00fchrt ein neues Pr\u00fcf- und Zulassungsverfahren f\u00fcr Arzneimittel ein, wodurch die Gesamtpr\u00fcfungszeit auf nur 21 Tage verk\u00fcrzt wird. Lesen Sie mehr unter RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/zulassung-von-arzneimitteln-durch-die-nmpa-in-china\/","og_locale":"de_DE","og_type":"article","og_title":"NMPA Approves First Clinical Trial Application Under Pilot Program for Innovative Drugs","og_description":"China's NMPA introduces a new review and approval process for drugs, reducing the total review time to only 21 days. Read more at RegASK.","og_url":"https:\/\/regask.com\/de\/zulassung-von-arzneimitteln-durch-die-nmpa-in-china\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-12-02T12:58:50+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#article","isPartOf":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"NMPA Approves First Clinical Trial Application Under Pi&hellip;","datePublished":"2024-12-02T12:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/"},"wordCount":266,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","keywords":["Oncology","Drug Development Regs","Clinical Trial Regulations"],"articleSection":["Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","url":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/","name":"\u00dcberpr\u00fcfungs- und Zulassungsverfahren f\u00fcr neue Arzneimittel der chinesischen NMPA | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","datePublished":"2024-12-02T12:58:50+00:00","description":"Die chinesische NMPA f\u00fchrt ein neues Pr\u00fcf- und Zulassungsverfahren f\u00fcr Arzneimittel ein, wodurch die Gesamtpr\u00fcfungszeit auf nur 21 Tage verk\u00fcrzt wird. Lesen Sie mehr unter RegASK.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/china-nmpa-drug-review-approval\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/china-nmpa-drug-review-approval\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/12\/nmpa-approves-first-clinical-trial-application-under-pilot-program-innovative-drugs.png","width":800,"height":600,"caption":"Nmpa Approves First Clinical Trial Application Under Pilot Program Innovative Drugs"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=7862"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/7862\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/7872"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=7862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=7862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=7862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}